Patents by Inventor Gavin Charles Hirst

Gavin Charles Hirst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC KINASE MODULATORS
    Publication number: 20090156594
    Abstract: The present disclosure provides heterocyclic protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.
    Type: Application
    Filed: May 21, 2008
    Publication date: June 18, 2009
    Applicant: SGX Pharmaceuticals, Inc.
    Inventors: Pierre-Yves Bounaud, Christopher Ronald Smith, Elizabeth A. Jefferson, Jorg Hendle, Patrick S. Lee, Angelina Marie Thayer, Gavin Charles Hirst
  • Oxoazepine derivatives
    Patent number: 6096885
    Abstract: This invention relates to novel oxoazepine derivatives of Formula (I),R.sup.1 R.sup.2 NCOCH.sub.2 N(R.sup.3)COR.sup.4 (I)to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: August 1, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Milana Dezube, Gavin Charles Hirst, Ronald George Sherrill, Elizabeth Ellen Sugg, Jerzy Ryszard Szewczyk, Timothy Mark Willson
  • Oxoazepine derivatives
    Patent number: 5889182
    Abstract: This invention relates to novel oxoazepine derivatives of Formula (I),R.sup.1 R.sup.2 NCOCH.sub.2 N(R.sup.3)COR.sup.4 (I)to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals.
    Type: Grant
    Filed: April 14, 1997
    Date of Patent: March 30, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Milana Dezube, Gavin Charles Hirst, Ronald George Sherrill, Elizabeth Ellen Sugg, Jerzy Ryszard Szewczyk, Timothy Mark Willson
  • CCK or gastrin modulating benzo ?b!?1,4! diazepines derivatives
    Patent number: 5859007
    Abstract: Benzo?b!?1,4!diazepine compounds of formula (I), where R.sup.1 is selected from C.sub.1 C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is selected from C.sub.3 -C.sub.6 alkyl, C.sub.3 C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 alkenyl, benzyl, phenylC.sub.1 -C.sub.3 alkyl of substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl C.sub.1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R.sup.3, R.sup.5, and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkenyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR.sup.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: January 12, 1999
    Assignee: Glaxo Wellcome Inc.
    Inventors: Christopher Joseph Aquino, Marcus Brackeen, Milana Dezube, Brad Richard Henke, Gavin Charles Hirst, Peter Walter Jeffs, Tanya Momtahen, Elizabeth Ellen Sugg, Edward Martin Suh, Timothy Mark Willson